SCHEMBL2247757

SCHEMBL2247757

S=c1[nH]cc(-c2cc(C3CCCC3)cs2)[nH]1

nearest known ligand 0.36

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.36
KDM5B Q9UGL1 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2246612 0.98 HDAC8 (0.35) HDAC8KDM5BKDM4EGAAGFER
SCHEMBL2246622 0.94 HDAC8 (0.38) HDAC8KDM5BKDM4EGAAGFER
SCHEMBL2250817 0.74 GFER (0.39) HDAC8KDM4EGAAGFER
SCHEMBL639462 0.73 KDM4E (0.53) HDAC8KDM4EGAAGFER
SCHEMBL2243279 0.73 GFER (0.38) HDAC8KDM4EGAAGFER
SCHEMBL638653 0.72 KDM4E (0.51) HDAC8KDM4EGAAGFER
SCHEMBL639698 0.72 GFER (0.51) HDAC8KDM4EGAAGFER
SCHEMBL638661 0.71 GFER (0.50) HDAC8KDM4EGAAGFER
SCHEMBL2247903 0.68 KDM3B (0.40) HDAC8KDM4EGAAGFER
SCHEMBL2245856 0.67 GFER (0.41) HDAC8KDM4EGAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989483-B2 4-heteroarylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-08-02 US claimed
US-20100144813-A1 NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US claimed
EP-2164845-A1 NOVEL 4-HETEROARYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY Galderma Research & Development (FR) 2010-03-24 EP claimed
WO-2008152332-A1 NOVEL 4-HETEROARYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO claimed
US-7989483-B2 4-heteroarylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-08-02 US disclosed
US-20100144813-A1 NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US disclosed
EP-2164845-A1 NOVEL 4-HETEROARYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY Galderma Research & Development (FR) 2010-03-24 EP disclosed
WO-2008152332-A1 NOVEL 4-HETEROARYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144813-A1 NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF TYR, TH, NAT1 HDAC8 382/4885KDM5B 595/4885KDM4E 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.